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Abstract
Osteoarthritis is often a progressive and disabling disease, which
occurs in the setting of a variety of risk factors - such as advancing
age, obesity, and trauma - that conspire to incite a cascade of
pathophysiologic events within joint tissues. An important emerg-
ing theme in osteoarthritis is a broadening of focus from a disease
of cartilage to one of the ‘whole joint’. The synovium, bone, and
cartilage are each involved in pathologic processes that lead to
progressive joint degeneration. Additional themes that have
emerged over the past decade are novel mechanisms of cartilage
degradation and repair, the relationship between biomechanics
and biochemical pathways, the importance of inflammation, and the
role played by genetics. In this review we summarize current
scientific understanding of osteoarthritis and examine the patho-
biologic mechanisms that contribute to progressive disease.
Introduction
Osteoarthritis (OA) is characterized by a progressive loss of
articular cartilage accompanied by new bone formation and,
often, synovial proliferation that may culminate in pain, loss of
joint function, and disability. A variety of etiologic risk factors and
pathophysiologic processes contribute to the progressive
nature of the disease and serve as targets of behavioral and
pharmacologic interventions. Risk factors such as age, sex,
trauma, overuse, genetics, and obesity can each make
contributions to the process of injury in different compartments
of the joint. Such risk factors can serve as initiators that promote
abnormal biochemical processes involving the cartilage, bone,
and synovium, which over a period of years result in the
characteristic features of OA: degradation of articular cartilage,
osteophyte formation, subchondral sclerosis, meniscal
degeneration, bone marrow lesions, and synovial proliferation.
Risk factors for osteoarthritis
Genetic predisposition
A genetic disposition to OA has been clear since it was first
reported by Kellgren and coworkers [1] that generalized
nodal OA was twice as likely to occur in first-degree relatives
as in control individuals. Twin pair and family risk studies have
indicated that there is a significantly higher concordance for
OA between monozygotic twins than between dizygotic
twins, and that the hereditable component of OA may be in
the order of 50% to 65% [2]. However, because of the
prevalence of OA in the general population and extensive
clinical heterogeneity, the precise genetic contribution to the
pathogenesis of OA has been difficult to analyze. Moreover, it
is clear that multiple genetic factors can contribute to the
incidence and severity of OA, and that these may differ
according to specific joint (hand, hip, knee, or spine), sex, and
race. There is also evidence, given the variety of candidate
genes that predispose to OA, that there may be an additive
effect of individual genes in the development of disease [3].
Several candidate genes encoding proteins of the extra-
cellular matrix of the articular cartilage have been associated
with early-onset OA [4]. In addition to point mutations in type
II collagen [5], inherited forms of OA may be caused by muta-
tions in several other genes that are expressed in cartilage,
including those encoding types IV, V, and VI collagens, as
well as cartilage oligomeric matrix protein (COMP) [6].
Candidate genes for OA have also been identified that are
not structural proteins. Among such candidates are the
secreted frizzled-related protein 3, asporin, and von Wille-
brand factor genes [7,8]. In follow-up studies it has been
reported that the asporin, frizzled-related protein 3, and von
Willebrand factor genes have now been found not to
replicate in large Caucasian meta-analyses and that the
association with growth differentiation factor (GDF)-5 in
Caucasians has been confirmed in larger meta-analyses
[9-12]. Finally, evidence from mouse models indicates that
genetic disorders affecting the architecture of subchondral
bone can cause OA. Mice with a null mutation of the latent
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transforming growth factor (TGF)-β binding protein-3, which
regulates the activation of TGF-β, developed both osteo-
sclerosis and OA [13]. In addition, a recent report
demonstrated that a genetic defect of type I collagen resulted
in rapidly progressive OA in a mouse model [14].
In recent population studies, genome-wide linkage scans
have highlighted several specific genes involved in disease
risk [15]. Chromosome 2q was positive in several scans,
suggesting that this chromosome is likely to harbor one or
more susceptibility genes. Two IL-1 genes (IL1α and IL1β)
and the gene encoding IL-1 receptor antagonist (IL1RN),
located on chromosome 2q13 within a 430-kilobase genomic
fragment, have been shown to associate with the
development of primary knee, but not hip, OA [16]. IL1RN
haplotype variants have also been shown to associate with
radiographic severity of the OA [17]. Recently, a genome-
wide association scan has identified a cyclo-oxygenase
(COX)-2 variant involved in risk for knee OA [18]. These
genetic associations of genes such as IL1α, IL1β, IL1RN,
and  COX2 underscore the potential role of inflammatory
pathways in the pathogenesis of knee OA.
Age
Age is the risk factor most strongly correlated with OA, and
therefore understanding age-related changes is essential.
Age-related mechanical stress on joint cartilage may arise
from a number of factors, including altered gait, muscle
weakness, changes in proprioception, and changes in body
weight. In addition, age-related morphologic changes in
articular cartilage are most likely due to a decrease in
chondrocytes’ ability to maintain and repair the tissue. This is
because chondrocytes themselves undergo age-related
decreases in mitotic and synthetic activity, exhibit decreased
responsiveness to anabolic growth factors, and synthesize
smaller and less uniform large aggregating proteoglycans and
fewer functional link proteins [19]. Age also appears to be an
independent factor that predisposes articular chondrocytes
to apoptosis, because the expression levels of specific pro-
apoptotic genes (those encoding Fas, Fas ligand, caspase-8,
and p53) are higher in aged cartilage [20,21].
Obesity
Obesity is another important risk factor for OA [22]. An
increase in mechanical forces across weight-bearing joints is
probably the primary factor leading to joint degeneration. The
majority of obese patients exhibit varus knee deformities,
which result in increased joint reactive forces in the medial
compartment of the knee, thereby accelerating the degenera-
tive process [23]. Emerging data implicate a crucial role for
adipocytes in regulation of cells present in bone, cartilage,
and other tissues of the joint. The comparatively recently
discovered protein leptin may have important involvement in
the onset and progression of OA, and increase our
understanding of the link between obesity and OA [24]. In
addition, adipocyte-derived factors such as IL-6 and C-
reactive protein appear to be pro-catabolic for chondrocytes.
Further work is needed to determine whether leptin or other
adipokines are important systemic or local factors in the link
between obesity and OA.
Joint malalignment
Whether joint malalignment leads to the development of OA
is a matter of debate [25]. However, the evidence does
indicate that varus or valgus deformities are markers of
disease severity and are associated with risk for progression
of knee OA [26]. Indeed, there is evidence to suggest that
much of the effect of obesity on the severity of medial
compartment knee OA can be explained by varus mal-
alignment [27]. Hunter and colleagues [28] have reported
that enlarging or new bone marrow lesions occurred mostly in
malaligned limbs, on the side of the malalignment. With
regard to mechanisms, altered joint geometry may interfere
with nutrition of the cartilage, or it may alter load distribution,
either of which may result in altered biochemical composition
of the cartilage [29].
Sex
Although hip OA is slightly more common in men, there is a
marked increase in prevalence among women after the age of
50 years, particularly in the knee, and the cause of this
increase - which has been ascribed to estrogen insufficiency -
is poorly understood [30]. Articular chondrocytes possess
functional estrogen receptors, and there is evidence that
estrogen can upregulate proteoglycan synthesis [31]. In
support of a role for estrogens in OA, there are human and
animal studies indicating that estrogen replacement therapy
reduces the incidence of OA [32,33], although prospective
randomized trials to confirm these observations, particularly
with respect to structure modification, have not been
performed. It should be noted, however, that the evidence for
a relation between estrogen deficiency and OA in women is
inconsistent, and one 4-year study showed no effect of
estrogen plus progestin versus placebo on symptoms or
disability in postmenopausal women [34].
The pathobiology of osteoarthritis
Biomechanics and loading: chondrocytes as
mechano-sensors
Chondrocytes embedded within the negatively charged
cartilaginous extracellular matrix are subjected to mechanical
and osmotic stresses [35-37]. One of the most exciting
emerging areas is that chondrocytes, like osteocytes in bone,
serve as mechano-sensors and osmo-sensors, altering their
metabolism in response to local physicochemical changes in
the microenvironment. Therefore, while obesity and joint
misalignment are risk factors for OA in specific joints, the
mechanism by which these risk factors initiate and perpetuate
OA is largely mediated by biochemical pathways. Several
groups have identified osmo-sensors and mechano-sensors
in chondrocytes in the form of several ion channels, sulfate
transporters and integrins [35-37]. In response to mechanicalstress, changes in gene expression and an increase in
production of inflammatory cytokines and matrix-degrading
enzymes have been noted (Figure 1) [38]. The recognition
that chondrocytes act as mechano-sensors and osmo-
sensors has opened up the possibility that these proteins
could serve as novel targets for disease-modifying OA drugs.
Degeneration of articular cartilage in osteoarthritis:
cartilage degradation
OA is characterized by a loss of articular cartilage matrix,
which is the result of the action of proteolytic enzymes that
degrade both proteoglycans (aggrecanases) and collagen
(collagenases). Native collagen has been shown to be
cleaved by matrix metalloproteinase (MMP)-1, MMP-8, and
MMP-13. Of the three major MMPs that degrade native
collagen, MMP-13 may be the most important in OA
because it preferentially degrades type II collagen [39] and it
has also been shown that expression of MMP-13 greatly
increases in OA [40]. Among the characteristic changes in
OA cartilage is the development of the hypertrophic
chondrocyte phenotype, characterized by increased produc-
tion of MMP-13, type X collagen, and alkaline phosphatase.
Kawaguchi [41] has provided evidence that the induction of
the transcriptional activator Runx2 (runt-related transcription
factor 2) under mechanical stress in turn induces the
hypertrophic phenotype, which leads to type II collagen
degradation (MMP-13 production), endochondral ossifica-
tion, and chondrocyte apoptosis.
The aggrecanases belong to a family of extracellular
proteases known as the ADAMTS (a disintegrin and metallo-
protease with thrombospondin motifs) [39]. Two aggrecanases,
ADAMTS-4 and ADAMTS-5, appear to be major enzymes in
cartilage degradation in OA [40]. Recently, an ADAMTS-5
knock-out mouse and ADAMTS-5-resistant aggrecan knock-
in mouse, both of which show protection from OA, have
validated ADAMTS-5 as a target for OA [42,43].
IL-1 stimulates the synthesis and secretion of many degra-
dative enzymes in cartilage, including latent collagenase,
latent stromelysin, latent gelatinase, and tissue plasminogen
activator [44]. The balance of active and latent enzymes is
regulated by at least two enzyme inhibitors: tissue inhibitor of
metalloproteinases and plasminogen activator inhibitor-1
[45]. These enzyme inhibitors are synthesized in increased
amounts under the regulation of TGF-β.
Degeneration of articular cartilage in osteoarthritis:
cartilage synthesis
The metabolic imbalance in OA includes both an increase in
cartilage degradation and an insufficient reparative or
anabolic response. The identification of anabolic agents that
can be utilized to restore cartilage is an area of significant
investigation. Molecules of interest include cartilage anabolic
factors such as bone morphogenetic proteins, insulin-like
growth factor-I, TGF-β, and fibroblast growth factors. Growth
factors such as bone morphogenetic proteins have the ability
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Figure 1
Molecular and cellular mechanisms that perpetuate osteoarthritis. BMP, bone morphogenetic protein; MMP, matrix metalloproteinase; NO, nitric
oxide; PA, plasminogen activator; PG, prostaglandin; TGF, transforming growth factor; TIMP, tissue inhibitor of MMP; TNF, tumor necrosis factor.
Adapted from Abramson and coworkers [79].to reverse catabolic responses by IL-1 [46]. Conversely,
normal chondrocytes exposed to IL-1 or chondrocytes from
OA patients exhibit decreased responsiveness to growth
factors [47]. An understanding of the interaction between
catabolic cytokines and anabolic growth factors could lead to
the identification of molecules that restore the responsive-
ness of diseased chondrocytes to anabolic growth factors or
inhibitors of inflammatory cytokines.
Degeneration of articular cartilage in osteoarthritis:
inflammation
The role played by inflammatory cytokines and mediators
produced by joint tissues in the pathogenesis of OA is attracting
increased attention. Among the many biochemical pathways
that are activated within joint tissues during the course of OA
are mediators classically associated with inflammation, notably
IL-1β and tumor necrosis factor (TNF)-α. These cytokines, in an
autocrine/paracrine manner, stimulate their own production and
induce chondrocytes to produce proteases, chemokines, nitric
oxide, and eicosanoids such as prostaglandins and leukotrienes.
The action of these inflammatory mediators within cartilage is
predominantly to drive catabolic pathways, inhibit matrix
synthesis, and promote cellular apoptosis. Thus, although OA is
not conventionally considered an inflammatory arthritis, that
concept - based historically on the numbers of leukocytes in
synovial fluid - should be reconsidered. Indeed, ‘inflammatory’
mediators perpetuate disease progression and therefore
represent potential targets for disease modification.
Cytokines and chemokines
As noted above, a characteristic feature of established OA is
increased production of pro-inflammatory cytokines, such as
IL-1β and TNF-α, by articular chondrocytes. Both IL-1β and
TNF-α exert comparable catabolic effects on chondrocyte
metabolism, decreasing proteoglycan collagen synthesis and
increasing aggrecan release via the induction of degradative
proteases [48]. IL-1β and TNF-α also induce chondrocytes
and synovial cells to produce other inflammatory mediators,
such as IL-8, IL-6, nitric oxide, and prostaglandin E2. The
actions of both cytokines are in part mediated by activation of
the transcription factor nuclear factor-κB, which further
increases their own expression and that of other catabolic
proteins such as inducible nitric oxide synthase (iNOS) and
COX-2, thus creating an autocatalytic cascade that promotes
self-destruction of articular cartilage [49].
IL-1β and TNF-α are both synthesized intracellularly as pre-
cursors, converted through proteolytic cleavage to their mature
forms by caspases - membrane-bound IL-1β-converting
enzyme (ICE) and TNF-α-converting enzyme (TACE) - and
released extracellularly in their active forms. The expression of
both ICE and TACE has been shown to be upregulated in
OA cartilage [50]. Inhibitors of both ICE and TACE are of
interest as future therapeutic small-molecule antagonists of
downstream IL-1β and TNF-α expression, respectively; studies
with an ICE inhibitor are now underway in two murine models.
Osteoarthritic cartilage is also the site of increased
production of both C-X-C and C-C chemokines. These
include IL-8, monocyte chemoattractant protein-1, and
RANTES (regulated on activation, normal T-cell expressed
and secreted; also known as C-C chemokine ligand-5), as
well as the receptors C-C chemokine receptor (CCR)-2 and
CCR-5 [51]. RANTES induces expression of its own
receptor, CCR-5, which suggests an autocrine/paracrine
pathway of the chemokine within the cartilage. Monocyte
chemoattractant protein-1 and RANTES promote chondro-
cyte catabolic activities, including induction of nitric oxide
synthase, increased MMP-3 expression, inhibition of proteo-
glycan synthesis, and enhancement of proteoglycan release.
Prostaglandins
Chondrocytes from human OA cartilage explants express
COX-2 and spontaneously produce prostaglandin E2 [52].
We have recently reported that prostaglandin E2 produced by
OA cartilage explants decreases proteoglycan synthesis and
enhances the degradation of both aggrecan and type II
collagen. These effects are associated with downregulation
of MMP-1 and upregulation of MMP-13 and ADAMTS-5, and
are mediated via engagement of the prostaglandin E receptor
4 (EP4) [53]. How the divergent synthesis of MMP-1 and
MMP-13 is regulated remains unknown, but we previously
reported that upregulation of the nuclear orphan receptor
NURR1 (NR4A2) in OA cartilage causes similar divergent
effects. This suggests that the effect of prostaglandin E2 on
MMP-1 and MMP-13 may be a result of NURR1 activation
(NR4A2) [54]. In their interesting recent report of a genome-
wide scan, Valdes and coworkers [18] identified a COX-2
variant that was associated with increased risk for knee OA -
a finding that underscores the possible importance of this
signaling pathway in the pathogenesis of knee OA.
Reactive oxygen species
Among the inflammatory mediators that are of interest in the
pathogenesis of OA are both oxygen and nitrogen-derived
free radicals. Reactive oxygen species such as superoxide
anion, hydrogen peroxide, and hydroxyl radicals directly
promote chondrocyte apoptosis, most probably via mito-
chondrial dysfunction [55,56].
Nitric oxide
Nitric oxide, produced by the inducible isoform of nitric oxide
synthase (iNOS), is a major catabolic factor produced by
chondrocytes in response to pro-inflammatory cytokines such as
IL-1β and TNF-α [57]. Considerable evidence indicates that the
overproduction of nitric oxide by chondrocytes plays a role in the
perpetuation of cartilage destruction in OA. Although normal
cartilage does not express iNOS or produce nitric oxide without
stimulation by cytokines such as IL-1, OA cartilage explants
spontaneously produce large amounts of nitric oxide [58].
Nitric oxide exerts multiple effects on chondrocytes that
promote articular cartilage degradation [57]. These include
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of metalloproteinases; increased susceptibility to injury by other
oxidants (for example, hydrogen peroxide); and apoptosis.
Several studies have implicated nitric oxide as an important
mediator in chondrocyte apoptosis, a feature that is common in
progressive OA. There is evidence that apoptosis results from
the formation of peroxynitrite, a toxic free radical produced by
the reaction of nitric oxide and superoxide anion [59].
Nitric oxide and its derivatives may also play protective roles,
however, because protease activity and proteoglycan
degradation are enhanced when nitric oxide production is
blocked [60]. In murine models the development of surgically
induced OA can be accelerated in mice that are knocked out
for IL-1β, IL-1-converting enzyme, or iNOS. This suggests
that a certain level of these molecules may be necessary to
maintain a healthy joint and that complete pharmacologic
suppression may be detrimental [61]. The protective roles
played by nitric oxide in multiple cell types may reflect
differing properties of the redox form of the molecule
produced in the microenvironment [62].
Abnormalities of bone
Osteophyte formation and sclerosis of subchondral bone are
hallmarks of OA. It has been theorized that osteophytes occur
as a result of penetration of blood vessels into the basal
layers of degenerating cartilage, or as a result of abnormal
healing of stress fractures in the subchondral trabeculae near
the joint margins [63]. TGF-β, when introduced into the joint
in experimental animals, induces osteophyte formation, and
TGF-β expression is observed in osteophytes in patients with
OA [64,65].
With regard to subchondral bone sclerosis, it has been
suggested that excessive loads may cause microfractures of
subchondral trabeculae that heal via callus formation and
remodeling. Whether subchondral sclerosis precedes the
onset of OA or is a change that occurs but is not required for
cartilage degeneration is not known. However, strategies
targeted at bone disorders such as osteoporosis, and
molecular targets that alter osteoclast and/or osteoblast
function may represent opportunities to modulate pathologic
subchondral changes in OA, and are therefore under con-
sideration in efforts to develop disease-modifying treatments.
Bone marrow lesions
Felson and coworkers [66] reported that medial bone marrow
lesions observed on magnetic resonance imaging (MRI) are
associated with both knee pain and the risk for disease
progression. However, it should be noted that, depending on
size and location, the significance of bone marrow lesions in
the individual patient might vary. The presence of bone
marrow lesions and their relation to progression has been
explained in part by an association with limb alignment [66].
The histopathologic nature of bone marrow lesions in OA is
not yet clear, and it is probable that a number of tissue
abnormalities such as microfractures, cysts, and avascular
necrosis may contribute to the MRI findings.
Synovial proliferation and inflammation
It is increasingly appreciated that some degree of synovitis
may be observed even in early OA [67]. Synovial histologic
changes include synovial hypertrophy and hyperplasia, with
an increased number of lining cells, often accompanied by
infiltration of the sublining tissue with scattered foci of
lymphocytes [68]. Synovitis is often localized and may be
asymptomatic. Arthroscopic studies suggest that localized
proliferative and inflammatory changes of the synovium occur
in up to 50% of OA patients, and the activated synovium may
produce proteases and cytokines that accelerate progression
of disease [69]. Cartilage breakdown products, derived from
the articular surface as a result of mechanical or enzymatic
destruction of the cartilage, can provoke the release of
collagenase and other hydrolytic enzymes from synovial cells
and macrophages. Cartilage breakdown products are also
believed to result in mononuclear cell infiltration and vascular
hyperplasia in the synovial membrane in OA. A consequence
of these low-grade inflammatory processes is the induction of
synovial IL-1β and TNF-α, which are probable contributors to
the degradative cascade. There are also reports of increased
numbers of immune cells in synovial tissue, such as activated
B cells and T lymphocytes, including evidence for a clonally
expanded, antigen-driven B-cell response that may contribute
to the development or progression of the disease [70].
Biomarkers
Among the more exciting advances in our understanding of
OA has come from the study of imaging and chemical
biomarkers, which have revealed new aspects about the
pathogenesis and progression of the disease.
Imaging biomarkers
Although conventional radiography is useful for the diagnosis
of established disease, it has shortcomings with respect to
the assessment of progressive disease. For example
radiographic images are insensitive to early change within
cartilage and bone and do not reveal synovial or meniscal
pathology. They also lack correlation with severity of
symptoms and are nonspecific measures of disease progres-
sion. The potential value of MRI as a ‘biomarker’ has been
illustrated by studies that indicate that the presence of either
bone marrow lesions [66] or meniscal disease [71] predict
patients with knee OA at higher risk for disease progression.
Techniques for the quantitative and functional assessment of
cartilage, synovium, and bone by MRI are advancing, making
it likely that MRI will eventually replace conventional radiology
as a more sensitive and specific measure of disease
progression [66,72]. In addition, functional MRI studies
(delayed gadolinium-enhanced MRI of cartilage or sodium
MRI), which detect biochemical changes of extracellular
matrix proteins in cartilage, have attracted great interest as
‘proof of mechanism’ biomarkers that might demonstrate in
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chondrocyte metabolism.
Biochemical markers
It is likely that biochemical markers will be used in conjunction
with imaging in order to establish stage of disease, predict
progression, and assess disease activity and progression in
OA. The Osteoarthritis Biomarkers Network, a consortium of
five National Institutes of Health-designated sites, has
recently proposed a classification scheme of biomarkers for
OA [73]. Five categories of biomarkers (captured in the
acronym BIPED) were proposed to aid the study of all
aspects of OA, from basic science research to clinical trials
(Table 1): burden of disease, investigative, prognostic,
efficacy of intervention, and diagnostic.
Burden of disease markers denote severity or extent of
disease in one or multiple joints. Some examples that are
elevated in populations of patients with hip or knee OA
include serum COMP, urinary carboxyl-terminal cross-linking
telopeptide of type II collagen (CTX-II), and serum hyaluronan
[74]. Candidate prognostic markers include serum COMP,
urinary CTX-II, serum hyaluronic acid [75], and pentosidine,
an advanced glycation end-product [76]. The available data
suggest that urinary CTX-II is of particular interest. Elevated
levels of CTX-II have also been found to predict progression
of joint space narrowing in both knee and hip OA. Moreover,
Garnero and coworkers [77] found that bone marrow
abnormalities on MRI significantly correlated with urine CTX-II
and that patients with highest baseline urinary CTX-II levels
were more likely to have worsening bone marrow
abnormalities at 3 months. Finally, urinary CTX-II increases
after menopause, consistent with the acceleration of OA in
postmenopausal women and raising an intriguing question
about the protective effect of estrogens in OA.
It should be noted, however, the predictive value of these
markers in clinical trials has yet to be proven and, as such,
Arthritis Research & Therapy    Vol 11 No 3 Abramson and Attur
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Table 1
Biomarkers of bone, cartilage and synovial turnover, and the BIPED classification
Tissue Molecule Markers of synthesis Markers of degradation BIPED classification
Bone Type I collagen PYDa B
NTX-Ia,b D
CTX-Ia,b P
Noncollagenous proteins Osteocalcinb P
Cartilage Type II collagen PIIANPb P
Total PIINP D
PIICPb,c D, P
CTX-IIa,c D, B, P, E
HELIX-IIa P
Coll 2-1a,b P
Coll 2-1 NO2
a,b P
C2Ca,b P, E
1,2Ca,b P, E
Aggrecan Epitope 846 (cartilage  E
contentc)
Nonaggrecan and  COMPb,c D, B, P
noncollagenous proteins
Pentosidinea,b P
Proteases and their inhibitors MMPsb B, P, E
TIMPsb B, P
Synovium Type III collagen GIc-GaI-PYDa E
Noncolagenous proteins YKL-40b,c B, E
Hayluronic acidb B, P
aUrine. bSerum. cSynovial fluid. BIPED, B (burden of disease), I (investigative), P (prognostic), E (efficacy of intervention), D (diagnostic); C1,2C,
assay that detects COL2-¾C (short) epitope; C2C, assay that detects COL2-¾C (long) epitope; Coll 2-1, 9-amino-acid peptide of type II
collagen; Coll 2-1 NO2, nitrated form of Coll 2-1; COMP, cartilage oligomeric protein; CTX-I, carboxyl-terminal cross-linked telopeptide of type I
collagen; CTX-II, C-terminal cross-linked telopeptide of type II collagen; Glc-Gal-PYD, glucosyl-galactosyl-pyridinoline; HELIX-II, helical type II
collagen; MMP, matrix metalloproteinase; NTX-I, N-terminal cross-linked telopeptide of type I collagen; PIIANP, N-propeptide IIA of collagen type II;
PIICP, C-propeptide of collagen type II; PIINP, N-propeptide II of collagen type II; PYD, pyridinoline; TIMP, tissue inhibitor of matrix
metalloproteinase; YKL-40, cartilage glycoprotein 39. Reproduced with permission from Rouseeau and Delmas [80].there remains a need to validate these and other new
biomarkers. Indeed, caution regarding the predictive value of
drug-induced declines in CTX-II has been raised by Bingham
and coworkers [78], who reported that risedronate decreases
biochemical markers of cartilage degradation but does not
decrease symptoms or slow radiographic progression in
patients with medial compartment OA of the knee.
Conclusion
During the past decade there have been significant
developments in the scientific understanding of OA. Aided by
advances in imaging technology, we have come to appreciate
that OA is a disease of the ‘whole joint’, which involves a
complex series of molecular changes at the cell, matrix, and
tissue levels and complex interactions between the tissues
that make up the joint. We are beginning to understand better
the mechanisms by which genetic, mechanical, and metabolic
risk factors initiate and perpetuate the biochemical changes
that lead to progressive failure of the joint. We are also
gaining a better appreciation of the processes of aging and
senescence that underlie disease mechanisms. These
discoveries have opened opportunities for the identification of
targets for therapeutic intervention, which hopefully will lead
to effective therapies that reduce the symptoms and slow the
progression of OA.
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